// App-Quantinova.ai

TP1252 : An adjuvant systems approach to develop vaccines against challenging diseases: Dioleoyl phosphatidylserine (DOPS) confers enhanced protection against malaria for VLP‐TRAP based vaccines

Researchers

Presenter

  • Heath

Principal Investigators

  • Cabral - Miranda G

  • Kramer MF

  • Skinner MA

  • Bachmann MF

Medical Centers

  • Allergy Therapeutics Ltd, Worthing, United Kingdom

  • The Jenner Institute, Nuffield Department of Medicine, Centre for Cellular and Molecular Physiology (CCMP), University of Oxford, Oxford, United Kingdom

  • Department of Ophthalmology, Inselspital, University of Bern, Bern, Switzerland

  • Bencard Allergie Gmbh, Munich, Germany

Locations

  • United Kingdom

  • Switzerland

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Obstetrics/Gynecology

Disease

  • Malaria

  • Twin-reversed arterial perfusion

Biomarkers

  • Translocator protein

  • Triiodothyronine receptor auxiliary protein

Drug/Treatment

  • Phosphatidylserine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved